Trial Profile
A clinical study of biomarkers of innate and adaptive immune activation associated with symptoms and immune responses after administration of a single dose of a quadrivalent inactivated split virus influenza vaccine to healthy young adults.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Aug 2020
Price :
$35
*
At a glance
- Drugs GSK 2321138A (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- 06 Aug 2020 Status changed from recruiting to completed.
- 28 Aug 2017 New trial record